DarioHealth Corp.(DRIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,803 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
DRIO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for DarioHealth Corp. (DRIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DRIO at 18.8/100 on a 32-signal composite quality model, placing it at rank #2,803 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (3.5) and profitability (5.8), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), DarioHealth Corp. reports quarterly revenue of $5.2M, net income of $-7.9M, free cash flow of $-6.1M. Top institutional holders of DRIO by reported 13-F value include Nantahala Capital Management, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. DRIO trades on the Nasdaq exchange and files with the SEC under CIK 1533998. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DRIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DarioHealth Corp. directly from SEC EDGAR. DarioHealth Corp.'s 13F Pro composite quality score has ranged between 8 and 28 since 2022, currently 18.8 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$5.2M
Net Income
Q2 2026
$-7.9M
Free Cash Flow
Q2 2026
$-6.1M
ROIC
Q2 2026
-30.1%
D/E Ratio
Q2 2026
0.56
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-17.3% YoYNet Income
+2.4% YoYOperating Income
+36.5% YoYEPS (Diluted)
-17.5% YoYTotal Assets
-7.4% YoYTotal Debt
+6.3% YoYOp. Cash Flow
+32.7% YoYFree Cash Flow
+32.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $22.4M -17.3% | $27.0M +32.9% | $20.4M -26.4% | $27.7M +34.8% | $20.5M +170.8% | $7.6M |
| Net Income | $-41.7M +2.4% | $-42.7M +28.1% | $-59.4M +4.4% | $-62.2M +19.0% | $-76.8M -160.7% | $-29.4M |
| Operating Income | $-36.7M +36.5% | $-57.7M -2.8% | $-56.2M +1.1% | $-56.8M +25.7% | $-76.5M -155.8% | $-29.9M |
| EPS (Diluted) | $10.12 -17.5% | $12.27 +535.8% | $1.93 -24.0% | $2.54 -37.6% | $4.07 +1.5% | $4.01 |
| Total Assets | $110.1M -7.4% | $118.9M +23.3% | $96.4M -19.1% | $119.2M +18.3% | $100.8M +184.6% | $35.4M |
| Total Debt | $30.7M +6.3% | $28.9M +1.3% | $28.5M -20.2% | $35.8M | $0.00 | — |
| Operating Cash Flow | $-25.9M +32.7% | $-38.6M -26.9% | $-30.4M +36.5% | $-47.8M +5.1% | $-50.4M -184.2% | $-17.7M |
| Free Cash Flow | $-26.1M +32.6% | $-38.7M -25.0% | $-31.0M +35.9% | $-48.3M +4.7% | $-50.7M -183.8% | $-17.9M |
Get alerted when DRIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for DarioHealth Corp. including:
Top Institutional Holders of DRIO
Nantahala Capital Management, LLC
$4.0M610,691 shVANGUARD CAPITAL MANAGEMENT LLC
$433.5K65,675 shGEODE CAPITAL MANAGEMENT, LLC
$383.3K58,035 shBlackRock, Inc.
$249.5K37,796 shVANGUARD FIDUCIARY TRUST CO
$246.8K37,387 shCITADEL ADVISORS LLC
$160.3K24,289 shNORTHERN TRUST CORP
$87.4K13,237 shVanguard Global Advisers, LLC
$21.9K3,321 shMORGAN STANLEY
$19.8K3,000 shOSAIC HOLDINGS, INC.
$12.5K1,900 sh
| Fund | Value | Shares |
|---|---|---|
| Nantahala Capital Management, LLC | $4.0M | 610,691 |
| VANGUARD CAPITAL MANAGEMENT LLC | $433.5K | 65,675 |
| GEODE CAPITAL MANAGEMENT, LLC | $383.3K | 58,035 |
| BlackRock, Inc. | $249.5K | 37,796 |
| VANGUARD FIDUCIARY TRUST CO | $246.8K | 37,387 |
| CITADEL ADVISORS LLC | $160.3K | 24,289 |
| NORTHERN TRUST CORP | $87.4K | 13,237 |
| Vanguard Global Advisers, LLC | $21.9K | 3,321 |
| MORGAN STANLEY | $19.8K | 3,000 |
| OSAIC HOLDINGS, INC. | $12.5K | 1,900 |
Companies Similar to DRIO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Xtant Medical Holdings, Inc.
Guardforce AI Co., Ltd.
Apyx Medical Corp
Keros Therapeutics, Inc.
NOODLES & Co
Scully Royalty Ltd.
USANA HEALTH SCIENCES INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put DRIO on your watchlist
Track score changes the day DarioHealth Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DRIO a good stock to buy?
13F Pro's AI-powered analysis of DarioHealth Corp. (DRIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DRIO are available on the DRIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DRIO is classified as a small company.
Which hedge funds own DRIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DRIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DarioHealth Corp.'s investment landscape.